Log in or Sign up for Free to view tailored content for your specialty!
Bone/Mineral Metabolism News
Study identifies CKD as risk factor for hip, nonvertebral fractures

A review of published studies revealed hip and nonvertebral fracture risks increased for patients with chronic kidney disease stages G3a-G5D, leading researchers to suggest CKD be considered as an additional risk factor for fractures.
Obesity may ‘blunt’ effect of race on bone parameters

Advantages in bone parameters that may contribute to reduced fracture risk among Black vs. white adolescents and young adults may be attenuated by obesity, according to findings published in Bone.
Log in or Sign up for Free to view tailored content for your specialty!
Resveratrol boosts bone density for postmenopausal women

A naturally occurring polyphenol in red grapes and berries may provide a prophylactic benefit for preventing bone loss in postmenopausal women without osteoporosis, according to data published in the Journal of Bone and Mineral Research.
Top data from ADA: SGLT2s, prescription fish oil, bempedoic acid address comorbidities

Healio and Endocrine Today have compiled a list of the most read news from the virtual American Diabetes Association Scientific Sessions.
Study: Vitamin D agents deemed similar for treating coronary artery calcification in CKD

Researchers found no difference in coronary artery calcification progression between patients with chronic kidney disease and secondary hyperparathyroidism who were randomized to either calcitriol or paricalcitol.
Combined oral contraceptives preserve bone density in primary ovarian insufficiency

Women with primary ovarian insufficiency prescribed combined oral contraceptives experienced an increase in bone density at the lumbar spine and total femur compared with similar women prescribed other hormone formulations or no treatment.
Osteoporosis treatment linked to adverse cardiovascular events

Evenity, a monoclonal antibody that inhibits sclerostin used to treat osteoporosis, may increase patients’ risk for adverse cardiovascular events, according to research published in Science Translational Medicine.
June endocrine drug approvals: new insulins, rare bone disease drug and more
In June, the FDA approved burosumab for a second rare bone disease, expanded the indication for an interoperable insulin pump, cleared an integrated continuous glucose monitor, and approved a biosimilar and a new faster-acting insulin.
FDA approves burosumab for tumor-induced osteomalacia

The FDA approved burosumab-twza injection to treat patients aged 2 years and older with tumor-induced osteomalacia, according to an agency press release.
Long-term heparin use may lead to reduced bone mineral density

Long-term use of unfractionated heparin may be associated with the loss of lumbar spine bone mineral density in patients undergoing maintenance hemodialysis treatment, according to a published study.
-
Headline News
Limiting daily TV time to 1 hour may reduce risk for atherosclerotic heart disease
March 12, 20253 min read -
Headline News
King Holmes, ‘giant’ of medicine and STI research, dies at 87
March 11, 20252 min read -
Headline News
Pregnancy may bring about persistent changes to the eye
March 10, 20252 min read
-
Headline News
Limiting daily TV time to 1 hour may reduce risk for atherosclerotic heart disease
March 12, 20253 min read -
Headline News
King Holmes, ‘giant’ of medicine and STI research, dies at 87
March 11, 20252 min read -
Headline News
Pregnancy may bring about persistent changes to the eye
March 10, 20252 min read